Efficacy and Safety of Secukinumab in Conjunction With Surgery in Moderate to Severe Hidradenitis Suppurativa

Peking Union Medical College

Status: Enrolling

Conditions: Secukinumab; Hidradenitis Suppurativa (HS); Hidradenitis Suppurativa (Acne Inversa)

Treatments: Combination Product: Surgery combined with secukinumab

Study type: Observational

Funder types: Other

Identifiers

NCT06926192

2025-KY-016

Details and patient eligibility

About

This study aims to retrospectively analyze the efficacy and safety of secukinumab combined with surgery in treating moderate to severe HS in real-world clinical practice, providing clinical practioners with real-world evidence in HS treatment.

Full description

Hidradenitis suppurativa (HS) is a chronic, recurrent, and disabling inflammatory disease that occurs in apocrine distribution sites such as the axilla, groin, and perianal region with a worldwide prevalence of approximately 1.5% -4.6%.The pathogenesis is excessive activation of the Th17 type immune response mediated by IL-17, IL-23, resulting in abnormal keratinization of hair follicles, obstruction of sebaceous ducts, and bacterial infection, culminating in abscesses, sinus tracts, and scarring.Patients with moderate to severe HS (Hurley stage II-III) often suffer from a severe decline in their quality of life due to recurrent infections, pain, and dysfunction, and their risk of depression is markedly elevated.Traditional treatments such as antibiotics, glucocorticoids, surgical debridement have limited efficacy, and the recurrence rate of surgery alone is as high as 50% -70%.In recent years, the use of biologic agents such as TNF-α inhibitors has dramatically improved HS outcomes, but 30% to 40% of patients still have an inadequate response to TNF-α inhibitors. Accumulating evidence suggests that the IL-17 pathway plays a key role in HS pathogenesis, that IL-17A expression is upregulated in the skin lesions of HS patients and positively correlates with disease severity. The efficacy and safety of secukinumab in combination with surgery remain unclear.

Enrollment: 100 estimated patients

Sex: All

Ages: Under 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Patients aged 18 to 80 years old with moderate-severe (Hurley II-III) HS
2. The diagnosis of HS was confirmed by histopathological examination in the Department of Pathology of our hospital
3. Patients with HS who received secukinumab combined with surgery in the Department of Dermatologic Surgery of our hospital
4. Patients with complete clinical data followed up for at least 1 year

Exclusion criteria

1. Patients lost to follow-up
2. Patients with less than one year of follow-up
3. Patients who received additional adjuvant therapy during the follow-up period

Trial design

100 participants in 1 patient group

Moderate to severe hidradenitis suppurativa

Treatment:

Combination Product: Surgery combined with secukinumab